Regenerex Pharma's SEC filings document the public-company reporting record of a Nevada wound-care issuer quoted under RGPX. Recent 8-K filings disclose governance and officer matters, including finance-function changes, board committee review, and reassignment of CFO duties, as well as a fiscal-year-end change and transition-period reporting.
The filing record also includes Form 12b-25 notices for delayed annual and quarterly reports, with narrative disclosures about completing financial statements and reconciling quarterly financial data. The filings identify the company as an emerging growth company, state that it has no securities registered under Section 12(b), and provide formal records on reporting obligations, governance oversight, financial-reporting controls, and capital-structure status.
Regenerex Pharma (RGPX) changed its fiscal year end to December 31. The Board approved moving the company’s fiscal year end from March 31 to December 31. To bridge the shift, the company will file a transition report on Form 10-K covering the period from April 1, 2025 through December 31, 2025.
This is an administrative change to align reporting periods. The upcoming transition 10-K will provide financials for the nine-month period noted before the new annual cycle begins on a calendar-year basis.